» Articles » PMID: 32627026

Long Noncoding RNA OSER1‑AS1 Promotes the Malignant Properties of Non‑small Cell Lung Cancer by Sponging MicroRNA‑433‑3p and Thereby Increasing Smad2 Expression

Overview
Journal Oncol Rep
Specialty Oncology
Date 2020 Jul 7
PMID 32627026
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

OSER1 antisense RNA 1 (OSER1‑AS1), a long noncoding RNA, has been well studied in the context of hepatocellular carcinoma. However, its expression status, specific functions, and tumorigenic mechanism in non‑small cell lung cancer (NSCLC) remain uninvestigated. Hence, this study aimed to assess OSER1‑AS1 expression, test the malignancy‑related biological functions of OSER1‑AS1, and illustrate how they affect NSCLC progression. OSER1‑AS1 expression in NSCLC was measured by reverse transcription‑quantitative polymerase chain reaction. Cell Counting Kit‑8 assay, flow cytometry, cell migration and invasion assay, and tumor xenograft assay were performed to analyze the effects of OSER1‑AS1 on the malignant phenotypes of NSCLC cells. Bioinformatics prediction with luciferase reporter and RNA immunoprecipitation assays were performed to determine the interaction between OSER1‑AS1 and microRNA‑433‑3p (miR‑433‑3p). OSER1‑AS1 was strongly expressed in NSCLC tissues and cell lines. Enhanced OSER1‑AS1 expression was significantly correlated with tumor size, TNM stage, and lymph node metastasis in patients with NSCLC. Patients with NSCLC exhibiting high OSER1‑AS1 expression had shorter overall survival than those exhibiting low OSER1‑AS1 expression. Functionally, a reduction in OSER1‑AS1 expression led to significant decreases in NSCLC cell proliferation, migration, and invasion as well as an increase in cell apoptosis in vivo. OSER1‑AS1 knockdown suppressed the tumorigenic ability of NSCLC cells in vivo. Mechanistically, OSER1‑AS1 acts as a competing endogenous RNA (ceRNA) in NSCLC cells by sponging miR‑433‑3p and thereby increasing the expression of mothers against decapentaplegic homolog 2 (Smad2). Finally, restoration experiments revealed that the suppression of miR‑433‑3p and restoration of Smad2 both counteracted the suppressive effects of OSER1‑AS1 depletion in NSCLC cells. Our findings illustrate the biological importance of the OSER1‑AS1/miR‑433‑3p/Smad2 pathway in NSCLC progression and offer a novel perspective regarding the identification of effective therapeutic and diagnostic targets.

Citing Articles

Exosome therapeutics for non-small cell lung cancer tumorigenesis.

Orooji N, Fadaee M, Kazemi T, Yousefi B Cancer Cell Int. 2024; 24(1):360.

PMID: 39478574 PMC: 11523890. DOI: 10.1186/s12935-024-03544-6.


SMAD Proteins in TGF-β Signalling Pathway in Cancer: Regulatory Mechanisms and Clinical Applications.

Wang Q, Xiong F, Wu G, Wang D, Liu W, Chen J Diagnostics (Basel). 2023; 13(17).

PMID: 37685308 PMC: 10487229. DOI: 10.3390/diagnostics13172769.


MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.

Matuszyk J Mol Med. 2022; 28(1):89.

PMID: 35922756 PMC: 9351108. DOI: 10.1186/s10020-022-00516-2.


LncRNA-m18as1 competitively binds with miR-18a-5p to regulate follicle-stimulating hormone secretion through the Smad2/3 pathway in rat primary pituitary cells.

Zhang W, Ren W, Han D, Zhao G, Wang H, Guo H J Zhejiang Univ Sci B. 2022; 23(6):502-514.

PMID: 35686528 PMC: 9198230. DOI: 10.1631/jzus.B2101052.


Regulation of apoptosis, autophagy and ferroptosis by non-coding RNAs in metastatic non-small cell lung cancer (Review).

Xu L, Huang X, Lou Y, Xie W, Zhao H Exp Ther Med. 2022; 23(5):352.

PMID: 35493430 PMC: 9019694. DOI: 10.3892/etm.2022.11279.


References
1.
Sibio S, Sica G, Di Carlo S, Cardi M, Di Giorgio A, Sollazzo B . Surgical treatment of intraperitoneal metastases from lung cancer: two case reports and a review of the literature. J Med Case Rep. 2019; 13(1):262. PMC: 6702753. DOI: 10.1186/s13256-019-2178-5. View

2.
Ma H, Wang L, Li W, Guo H, Wu Y, Li X . Upregulation of LINC00504 is associated with aggressive progression and poor prognosis in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2020; 24(2):699-703. DOI: 10.26355/eurrev_202001_20047. View

3.
Wang J, Huang Y, Song W, Li Y, Wang H, Wang W . Comprehensive analysis of the lncRNA‑associated competing endogenous RNA network in breast cancer. Oncol Rep. 2019; 42(6):2572-2582. PMC: 6826329. DOI: 10.3892/or.2019.7374. View

4.
Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M . A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011; 147(2):358-69. PMC: 3234495. DOI: 10.1016/j.cell.2011.09.028. View

5.
Li J, Liu S, Zhou H, Qu L, Yang J . starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2013; 42(Database issue):D92-7. PMC: 3964941. DOI: 10.1093/nar/gkt1248. View